Drug Discovery Platforms Industry

Direct Answer

Drug discovery platform companies use computing, automation or biology tools to find and design new drug candidates, then partner them out or develop them. Value comes from milestone payments, royalties and pipeline progress rather than product sales.

Industry Overview

Drug Discovery Platforms sits within the health care sector. The first numbers to compare across companies here are number of partnered programs, milestone and collaboration revenue and pipeline stage progression. The outside forces that move them are listed under Primary Macro Drivers.

Key Industry Metrics

• Number of partnered programs: Count of drug candidates being developed with pharmaceutical partners. More programs diversify the platform's chances, but quality matters: programs at later stages carry more value than early ones.
• Milestone and collaboration revenue: Income received from partners as programs reach agreed stages or as research is funded. It is lumpy and depends on partner decisions, so a single quarter says little about trend.
• Pipeline stage progression: Movement of candidates from discovery to preclinical to clinical trials. Progress through stages shows the platform is producing viable candidates; stalls point to scientific or funding issues.
• Cash runway: Months of operating spending covered by cash on hand. A short runway can force financing on unfavorable terms or cuts to programs.
• Platform validation by approved drugs: Whether drugs found with the platform reach regulatory approval. It is the strongest evidence the technology works, and few platforms have it, so check what stage the programs have reached.

Primary Macro Drivers

• Pharma outsourcing of discovery: Drugmakers hire platform firms to find candidates, so more outsourcing means more partnered programs and collaboration revenue.
• Biotech funding conditions: Funding conditions set how much cash these firms have to run their own programs, which affects cash runway and the pace of pipeline progress.
• Advances in machine learning and structural biology: Better models of protein structure and chemistry may speed up design and cut cost, which can raise the number and pace of candidates and partner interest.
• Partnering deals and milestones: Upfront payments, milestones and royalties from partners make up much of the revenue, so new deals and reached milestones show up in collaboration revenue.

Major Risks

• Unproven link from platform to approved drugs: A platform can find candidates without producing approved drugs, so value rests on later results; watch how many programs advance and what stage they reach.
• Funding dependence: Platform firms often spend more than they earn, so a weak funding market limits programs and may force dilution; watch cash and runway.
• Partner program terminations: A partner ending a program stops milestone payments and may lower the platform's credibility; watch termination notices and the count of partnered programs.
• Competition from big pharma tools: Drugmakers build their own computing and automation, which reduces what outside firms can charge; watch new partnerships and renewal terms.

Industry Characteristics

Companies Associated with Drug Discovery Platforms

The SEC's Standard Industrial Classification has no code that describes drug discovery platforms as a group, so there is no complete list of its filers. The companies below come from Swoopr's SEC dataset and have operations in or next to the industry. Each is classified by the SEC under its own main business.

Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. Listing here describes a business relationship to the industry, not a recommendation. To find more companies, use the company directory and the health care hub.

Where to Go Next

The Drug Discovery Platforms guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.

More in Health Care

• Health Care sector overview
• Electronic Health Records
• Digital Therapeutics
• European Pharmaceuticals
• Dialysis Centers
• Fertility Services
• Diagnostics & Post-Acute Care
• Gene Editing
• Diagnostic Laboratories

Put it to work

• How to analyze a stock
• Fundamental analysis guides
• Company research
• All industries

Frequently Asked Questions